Focus on cancer treatment and supportive care
First written in FY2016. 17 of 19 entries say "Restated". Latest entry: FY2026-H1.
1 other company's latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The Group conducts its business primarily by expanding and advancing its oncology pharmaceutical pipeline, including 3 products already on the market, and during the six-month period ended the second quarter of the current fiscal year, it engaged primarily in the following business activities.」
The Group continues to operate primarily around expanding and advancing its oncology pharmaceutical pipeline, including 3 products already on the market. - FY2025RestatedAnnual report
「The Group’s principal business area is the development and sale of pharmaceuticals for the treatment of malignant tumors. It also develops and sells pharmaceuticals and medical devices that are expected to reduce adverse events, including side effects, caused by the administration of cancer treatments or radiation therapy, thereby supporting the treatment of malignant tumors and improving patients’ quality of life (QOL).」
The Group continues to pursue a business policy covering anticancer drugs and supportive-care pharmaceuticals and medical devices that reduce adverse events associated with cancer treatment. - FY2023-Q3RestatedAnnual report
「The Group operates its business primarily by expanding and developing its oncology pharmaceutical pipeline, which includes 3 products already launched, and during the nine-month period ended in the third quarter of the current fiscal year, it primarily engaged in the following business activities.」
The Group continues to operate primarily around expanding and advancing its oncology pharmaceutical pipeline, including 3 products already on the market. - FY2023-Q2RestatedAnnual report
「The Group conducts its business primarily by expanding and advancing its oncology pharmaceutical pipeline, including 3 products already on the market.」
The Group continues to operate around its oncology pharmaceutical pipeline, including 3 products already on the market. - FY2023-Q1RestatedAnnual report
「The Group conducts its business primarily by expanding and advancing its oncology pharmaceutical pipeline, including 3 products already on the market.」
The Group continues to operate primarily around expanding and advancing its oncology pharmaceutical pipeline, including 3 products already on the market. - FY2022RestatedAnnual report
「The Group’s principal business area is the development and sale of pharmaceuticals for the treatment of malignant tumors. It also develops and sells pharmaceuticals and medical devices that are expected to reduce adverse events, including side effects, caused by the administration of cancer treatments or radiation therapy, thereby supporting the treatment of malignant tumors and improving patients’ quality of life (QOL).」
The Group continues to pursue a business policy covering anticancer drugs as well as supportive-care pharmaceuticals and medical devices that reduce side effects and other adverse events associated with cancer treatment. - FY2022-Q3AdvancedAnnual report
「The Group conducts its business primarily by expanding and advancing its oncology pharmaceutical pipeline, which comprises 3 products already on the market and 2 products in development.」
The pipeline composition changed from 2 products already on the market and 3 products in development to 3 products already on the market and 2 products in development, reflecting SP-02’s transition to the marketed stage. - FY2022-Q1RestatedAnnual report
「The Group conducts its business primarily by expanding and advancing its oncology pharmaceutical pipeline, which comprises 2 products already on the market and 3 products in development.」
The Group continues to operate around an oncology pharmaceutical pipeline comprising 2 products already on the market and 3 products in development. - FY2021-Q3RestatedAnnual report
「The Group conducts its business primarily by expanding and advancing its oncology pharmaceutical pipeline, which comprises 2 products already on the market and 2 products in late-stage development.」
The Group continues to operate around an oncology pharmaceutical pipeline comprising products already on the market and products in late-stage development. - FY2021-Q1RestatedAnnual report
「There were no significant changes in the business activities conducted by the Group (the Company and its affiliates) during the cumulative first quarter of the fiscal year under review. There were also no changes among the principal affiliates.」
There were no material changes to the Group’s established business of developing and selling pharmaceuticals and related products. - FY2020-Q3RestatedAnnual report
「There were no significant changes in the business activities conducted by the Group (the Company and its affiliates) during the cumulative third quarter of the fiscal year under review. There were also no changes among the principal affiliates.」
There were no material changes to the Group’s established business of developing and selling pharmaceuticals and related products. - FY2019-Q3RestatedAnnual report
「The Group’s principal business is the development and sale of pharmaceuticals and related products.」
There were no material changes to the Group’s established business of developing and selling pharmaceuticals and related products. - FY2019-Q1RestatedAnnual report
「There were no significant changes in the business activities conducted by the Group (the Company and its affiliates) during the cumulative first quarter of the fiscal year under review. There were also no changes among the principal affiliates.」
There were no material changes to the Group’s established business of developing and selling pharmaceuticals and related products. - FY2018-Q3RestatedAnnual report
「There were no significant changes in the business activities conducted by the Group (the Company and its affiliates) during the cumulative third quarter of the fiscal year under review. There were also no changes among the principal affiliates.」
There were no material changes to the Group’s established business of developing and selling pharmaceuticals and related products. - FY2018-Q2RestatedAnnual report
「There were no significant changes in the business activities conducted by the Group (the Company and its affiliates) during the cumulative second quarter of the fiscal year under review. There were also no changes among the principal affiliates.」
There were no material changes to the Group’s established business of developing and selling pharmaceuticals and related products. - FY2018-Q1RestatedAnnual report
「There were no significant changes in the business activities conducted by the Group (the Company and its affiliates) during the cumulative first quarter of the fiscal year under review.」
There were no material changes to the Group’s established business of developing and selling pharmaceuticals and related products. - FY2017RestatedAnnual report
「The Group’s principal business area is the development and sale of pharmaceuticals for the treatment of malignant tumors. It also develops and sells pharmaceuticals and medical devices that are expected to reduce adverse events, including side effects, caused by the administration of cancer treatments or radiation therapy, thereby supporting the treatment of malignant tumors and improving patients’ quality of life (QOL).」
The Group continues to focus on oncology drugs, supportive-care products and medical devices. - FY2017-Q3RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies) during the cumulative third quarter of the current fiscal year.」
There were no material changes to the Group’s established business of developing and selling pharmaceuticals and related products. - FY2016First statedAnnual report
「The Group’s principal business area is the development and sale of pharmaceuticals for the treatment of malignant tumors. It also develops and sells pharmaceuticals and medical devices that are expected to reduce adverse events, including side effects, caused by the administration of cancer treatments or radiation therapy, thereby supporting the treatment of malignant tumors and improving patients’ quality of life (QOL).」
The Group’s business scope includes not only anticancer drugs but also supportive care targeting conditions such as oral mucositis, nausea and vomiting associated with cancer treatment.